Navigation Links
Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
Date:4/20/2011

SAN FRANCISCO, April 20, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) ("the Company")and maintains its twelve month target price of $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "According to the Company, Opexa's lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is scheduled to advance into a pivotal Phase 3 clinical study in the U.S. in the second of half of 2011." Mr. Silver continued, "In clinical trials performed to date, Tovaxin® has compared favorably to already approved MS therapies, which are multi-billion dollar drugs. Of most significance in our opinion is Tovaxin® ranking ahead of both Copaxone® and Avonex® in Annualized Relapse Rate ("ARR"). ARR is possibly the most clinically relevant endpoint and is the single most important measure by which the FDA evaluates MS drugs for approval." Mr. Silver concluded, "Dendreon's Provenge®, the first FDA-approved autologous cellular immunotherapy which was recently approved by The Centers for Medicare and Medicaid Services for reimbursement of $93,000, has increased awareness and acceptance for this therapeutic approach."

To download a FREE copy of the Opexa Therapeutics, Inc. research report, please visit http://www.vistapglobal.com and complete the research form to gain access to the report.

About Vista Partners:

Vista Partners LLC, founded in 2005,  is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit the Vista Partners website at www.vistapglobal.com or click here.

Contact:
877.215.4813 or info@vistapglobal.com


'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
2. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
3. Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairss VistA Imaging System
4. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
5. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
6. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
7. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
8. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
9. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
10. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
11. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25, 2016 MedDay, a biotechnology company ... an oral presentation entitled "High doses of biotin in progressive ... be given by Professor Ayman Tourbah , Principal Investigator ... the European Academy of Neurology (EAN) in Copenhagen, ... 3" will take place on Sunday, 29 May 2016 from ...
(Date:5/24/2016)... AMSTERDAM , May 24, 2016 ... auf den Markt gebracht, die es Ärzten erlaubt, ... überall zu behandeln: MDLinking kombiniert Live Streaming mit ... sicheren Umfeld zu kommunizieren. Mediziner in Europa, Afrika, ... haben sich bereits für die Plattform registriert. ...
(Date:5/24/2016)... 24, 2016   , ... in overall bowel cleansing and superiority in ... leansing of the ascending ... , Norgine B.V. today announced new positive data from ... ascorbate bowel preparation) versus standard 2 litre PEG with ascorbate. The ...
Breaking Medicine Technology:
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated ... regulations. This is the first time that Coolsculpting is being used for for ... six months to ensure they meet the prescribed body-fat standard, measured by the circumference-based ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year ... complementary medicine. Allison Outerbridge is this year’s Life University winner of ... at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last ...
(Date:5/26/2016)... ... , ... There are many ways to cook a hot dog, but new ... prefer their dogs straight off the grill. Of the 90 percent of Americans who ... cook a hot dog, far outpacing other cooking methods such as steaming (12 percent), ...
(Date:5/26/2016)... Louis, Missouri (PRWEB) , ... May 26, 2016 ... ... cost, quality and clinical outcomes, hosted members and suppliers for its inaugural Member ... a focus on their mission of elevating the operational health of America’s healthcare ...
Breaking Medicine News(10 mins):